Lifeward Ltd. Material Event: A Critical Financial Update for Investors

Investors in Lifeward Ltd. need to understand a significant financial event that could impact their holdings. The company has recently entered into a new, high-stakes loan agreement. Let's break down the details.

---

1. What Happened? (The Event)

Lifeward Ltd. has secured a new, high-interest secured loan (officially called a secured promissory note) from Oramed Pharmaceuticals, Inc. This loan initially provides $525,000, but could increase to $1.5 million. The larger amount depends on Lifeward's shareholders approving certain related transactions with Oramed. Lifeward states the loan is for "general corporate purposes." This isn't Lifeward's first financial arrangement with Oramed; the company already owes Oramed Ltd. another $3.0 million from a previous loan.

2. When Did It Happen?

Lifeward and Oramed officially signed the agreement for this new loan on February 12, 2026. Lifeward then filed the necessary public disclosure paperwork with the SEC on February 19, 2026.

3. Why Did It Happen? (The Context)

This loan appears to be a critical and immediate source of capital for Lifeward's operations. Its terms suggest an urgent need for funds, possibly because the company faces challenges securing more traditional, lower-cost financing.

This new debt directly links to a broader strategic and financial arrangement with Oramed, specifically a Securities Purchase Agreement and a Share Purchase Agreement. Both require shareholder approval. These agreements likely involve Oramed acquiring additional equity or assets from Lifeward, positioning this loan as part of a larger financial restructuring or partnership.

4. Why Does This Matter? (The Impact)

This event carries significant implications for Lifeward and its investors:

• Extremely High Cost of Capital: The loan carries a staggering 24% annual interest rate. On the initial $525,000, this translates to an annual interest expense of at least $126,000. This substantial cost will directly and significantly reduce Lifeward's profitability and cash flow.
• Cash Collateral & Liquidity Risk: The loan is "secured by a lien on the Company’s cash." This means Oramed holds a priority claim on Lifeward's cash reserves. If Lifeward defaults, Oramed can seize its cash before other creditors. This severely limits Lifeward's financial flexibility, restricts its ability to use cash for other operational needs, and increases risk for unsecured creditors.
• Immediate Repayment Pressure & Shareholder Contingency: The loan is due for repayment by August 12, 2026. However, a critical condition states that if Lifeward's shareholders do not approve the related Securities Purchase Agreement and Share Purchase Agreement by May 12, 2026, the entire loan becomes due and payable immediately. This creates immense pressure on the company to secure shareholder approval and carefully manage its cash position.
• Oramed's Increasing Influence & Potential Dilution: With this new loan and the existing $3.0 million debt, Oramed is becoming a dominant financial stakeholder in Lifeward. The related Securities Purchase Agreement could potentially involve Oramed acquiring additional equity in Lifeward, which would lead to dilution (reducing the ownership percentage and value of existing shares) for current shareholders.
• Financial Health Concerns: Taking on such expensive, secured, and short-term debt often signals underlying financial strain, liquidity challenges, or an inability to access capital from traditional lenders. This raises questions about Lifeward's long-term financial stability and its ability to fund future growth.

5. Who Is Affected?

• Investors (Shareholders): Your investment in Lifeward could experience increased volatility due to the high-risk nature of this debt. Substantial interest payments will reduce earnings, potentially impacting share value. The potential for dilution from the related agreements and the company's increased financial leverage are significant concerns.
• Lifeward's Operations: The lien on cash limits operational flexibility. The short repayment timeline and the contingency on shareholder approval create significant strategic and financial pressure for the company.

6. What Happens Next? (Key Milestones)

Lifeward faces several critical upcoming milestones:

• Shareholder Vote: Lifeward's immediate focus will be on securing shareholder approval for the Securities Purchase Agreement and Share Purchase Agreement with Oramed by the critical deadline of May 12, 2026. Failure to do so will trigger immediate repayment of the $525,000 loan.
• Details of Related Agreements: Investors should closely monitor for the full details of the Securities Purchase Agreement and Share Purchase Agreement once Lifeward publicly discloses them. Understanding the terms of these agreements (e.g., whether they involve issuing new shares, selling assets, or other strategic shifts) is crucial for assessing the full impact on Lifeward.
• Debt Repayment Strategy: Lifeward must demonstrate a clear plan to either generate sufficient cash flow or secure alternative, more favorable financing to repay the loan by August 12, 2026, or sooner if the shareholder vote fails.
• Financial Reporting: Future financial reports will offer vital insights. Investors should scrutinize Lifeward's cash flow statements (showing money in and out), balance sheet (detailing debt levels and cash reserves), and income statement (revealing interest expense and net income) to assess the direct impact of this loan.

7. What Should Investors Know? (Practical Takeaways)

• High-Risk Financing: The 24% interest rate, cash collateral, and short repayment term signal a high-risk financing situation. This is a significant red flag regarding Lifeward's financial health.
• Critical Dates: Mark May 12, 2026 (shareholder approval deadline) and August 12, 2026 (loan maturity) on your calendar. These dates are pivotal for Lifeward's immediate future.
• Oramed's Strategic Role: Oramed's increasing financial ties to Lifeward suggest a growing influence. Understand the full scope of their relationship, especially once Lifeward releases the details of the related agreements.
• Dilution Potential: Be aware that the Securities Purchase Agreement could involve issuing new shares, potentially diluting the value of your existing holdings.
• Deep Dive Required: This event necessitates a thorough review of Lifeward's latest financial statements, its cash burn rate (how quickly it uses cash), and its overall business strategy. Assess whether this loan is a temporary bridge to a stronger position or a symptom of deeper financial distress.
• Monitor Closely: Expect continued volatility in Lifeward's stock. Watch for further announcements from the company, especially regarding the shareholder vote and the specifics of the related agreements.